Phase 2 RCT in 75 adults with erythropoietic protoporphyria: bitopertin 20 mg and 60 mg cut whole-blood protoporphyrin-IX by 29.6% and 49.8% vs placebo at day 121 (P=.004, P<.001); fewer phototoxic reactions, well tolerated.
RCTn = 75
Yeung et al. Bitopertin shows efficacy in patients with erythropoietic protoporphyria: Results from the randomized, double-blind, placebo-controlled AURORA trial